Basiliximab-Chimeric anti-IL2-R monoclonal antibody in pediatric liver transplantation: comparative study

• Published in: Transplantation proceedings 2004-05, Vol.36 (4), p.956-957
• Main Authors: Gibelli, N.E.M, Pinho-Apezzato, M.L, Miyatani, H.T, Maksoud-Filho, J.G, Silva, M.M, Ayoub, A.A.R, Santos, M.M, Velhote, M.C.P, Tannuri, U, Maksoud, J.G
• Format: Article
• Language: English
• Subjects: Adolescent; Antibodies, Monoclonal - therapeutic use; Biological and medical sciences; Body Weight; Child; Child, Preschool; Dose-Response Relationship, Drug; Graft Rejection - epidemiology; Humans; Immunomodulators; Immunosuppressive Agents - therapeutic use; Infant; Liver Transplantation - immunology; Liver, biliary tract, pancreas, portal circulation, spleen; Medical sciences; Pharmacology. Drug treatments; Postoperative Period; Receptors, Interleukin-2 - immunology; Recombinant Fusion Proteins - therapeutic use; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases; Surgery of the digestive system
• ISSN: 0041-1345; 1873-2623
• DOI: 10.1016/j.transproceed.2004.04.070

Basiliximab is a monoclonal antibody that binds to the α subunit (CD 25) of the interleukin-2 receptor of activated T lymphocytes. The advantage of basiliximab in organ transplantation is the reduce possibility to calcineurin inhibitor dosages to avoid nephrotoxicity. Basiliximab has significantly reduced the incidence of acute rejection (AR) in renal transplant recipients; however, the results are uncertain in liver transplantation (LT). The objective of this investigation was to assess the effect of basiliximab to prevent AR in the first 6 months after pediatric LT. From March 2000 to October 2001, 32 recipients of a primary orthotopic cadaveric or living donor LT were given basiliximab by intravenous bolus injection on the day of transplantation (day 0) and on day 4. Four children who received one dose were excluded from the study. The rate and the intensity of AR episodes, the incidence of chronic rejection, serum creatinine level, incidence of infections, adverse side effects, and daily oral dosage of cyclosporine (Neoral) to maintain the target blood level of 850 to 1000 mg/dL at C2, 2 hours after the administration, were analyzed in the remaining 28 recipients. Results were compared to those obtained from a matched historical group ( n = 28) of similar age, weight, and hepatic diseases distribution. None of the analyzed parameters was statistically significant ( P > .05) except for the daily oral dose of cyclosporine (7 to 13 mg/kg/dose, P < .05). In our series, the addition of basiliximab to the immunosuppressive therapy did not reduce the incidence of AR in pediatric LT.